Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Q-linea AB ( (SE:QLINEA) ) has provided an announcement.
Q-linea AB has announced a change in the number of shares and votes following the issuance of equalization shares and a reverse share split, resulting in a new total of 6,436,873 shares as of July 31, 2025. This restructuring is part of a broader financial strategy to optimize the company’s capital structure, with potential implications for shareholder value and market positioning.
More about Q-linea AB
Q-linea is a company specializing in rapid antimicrobial susceptibility testing (AST) systems, notably their ASTar® system, which aids hospitals in quickly determining optimal antimicrobial therapies for patients with bloodstream infections and sepsis. Headquartered in Uppsala, Sweden, Q-linea operates with regional offices in Italy and the USA and maintains global partnerships. Their products are CE-IVD marked and FDA 510(k) cleared.
Average Trading Volume: 27,262
Technical Sentiment Signal: Sell
Current Market Cap: SEK323.7M
For a thorough assessment of QLINEA stock, go to TipRanks’ Stock Analysis page.